"Annals of Oncology" . "RIV/61989592:15110/08:00007569" . "Prvn\u00ED linie bevacizumabu v kombinaci s redukovanou d\u00E1vkou interferonu-\u03B12a je aktivn\u00ED u pacient\u016F s karcinomem ledviny"@cs . . "This retrospoective subgroup analysis suggests that the dose od IFN can be reduced to manager side-effects while maintaining efficacy in patiens with mrcci recweiving bevacizumat + IFN"@en . "368120" . "S" . "1"^^ . . . "RIV/61989592:15110/08:00007569!RIV09-MSM-15110___" . . "Prvn\u00ED linie bevacizumabu v kombinaci s redukovanou d\u00E1vkou interferonu-\u03B12a je aktivn\u00ED u pacient\u016F s karcinomem ledviny"@cs . "Pops\u00E1n efekt redukce d\u00E1vky interferonu na \u00FA\u010Dinnost v kombinaci s bevacizumabem u karcinomu ledviny"@cs . "First-line bevacizumab combined with reduced dose interferon-2a is active in patients with metastatic renal cell carcinoma"@en . . "8" . "First-line bevacizumab combined with reduced dose interferon-2a is active in patients with metastatic renal cell carcinoma"@en . . "First-line bevacizumab combined with reduced dose interferon-2a is active in patients with metastatic renal cell carcinoma" . "Koralewski, P." . "[A5E5CE69CBC8]" . "Antiangiogenic therapy; bevacizumab; interferon-\u03B1; renal cell carcinoma; vascular endothelial growth"@en . "Revaud, A." . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . . "7"^^ . . . . "Bracarda, S." . . "0923-7534" . "Pluzanska, A." . "This retrospoective subgroup analysis suggests that the dose od IFN can be reduced to manager side-effects while maintaining efficacy in patiens with mrcci recweiving bevacizumat + IFN" . . "Melichar, Bohuslav" . "Szczyylik, C." . . . . "6"^^ . . "First-line bevacizumab combined with reduced dose interferon-2a is active in patients with metastatic renal cell carcinoma" . "19" . "15110" .